$2.11
-0.02 (-0.94%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where INMB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 2 with posted results
Held by 9 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, +4 more) · FINRA short interest 6.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study of INKmune in Patients With mCRPC (CaRe Prostate)NCT06056791Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: INKmune | Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC | 12 | 2025-09-10actual | 2026-02-27 |
| A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976results2026-06-29Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: XPro1595, Placebo | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Mild Cognitive Impairment | 207 | 2025-05-12actual | 2026-06-29 |
| An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387Number of participants who experience adverse events and serious adverse eventsOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor resource allocation | Drug: XPro1595 | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 11 | 2024-06-05actual | 2026-02-27 |
| A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AMLNCT05933070Primary Objective 1Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Slow/low Enrollment | Biological: INKmune | Cancer, MDS-EB, Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML | 2 | 2024-03-28actual | 2026-03-30 |
| Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationNCT05321498Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: MCI patients will now be enrolled in the XPro1595-AD-02 study. | Drug: XPro1595, Placebo | Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Mental Disorders | 0 | 2023-10-26 | 2023-09-28 |
| INB03 for the Treatment of Pulmonary Complications From COVID-19NCT04370236results2026-05-19Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease ProgressionRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Futility | Drug: INB03, Placebo | COVID-19 | 79 | 2021-10-13actual | 2026-05-19 |
| A Biomarker-directed Study of XPro1595 in Patients With Alzheimer'sNCT03943264The number of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: XPro1595 | Alzheimer Disease | 20 | 2021-06-30actual | 2023-06-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19